Clinical trials: Mesothelioma
Non-small Cell Lung Cancer, Small Cell Lung Cancer
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
The purpose of this study is to compare two types of care - standard oncology care and standard oncology care with early palliative care (started soon after diagnosis) to see which is better for improving the experience of…
- Conditions
- Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Esophageal Cancer
- Trial name
- NCT01401907
- Testing
- early palliative care
- Where
- United States
- Volunteers
- 351 people
- Sponsor
- Massachusetts General Hospital
Mesothelioma, Pleural Mesothelioma
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Patients with pleural mesothelioma that can not be surgically removed will receive durvalumab, in combination with standard chemotherapy of pemetrexed and cisplatin as first-line treatment.
- Trial name
- PrE0505 (NCT02899195)
- Testing
- Durvalumab
- Where
- 20 sites in United States
- Volunteers
- 55 people
- Sponsor
- PrECOG, LLC.
Pleural Malignant Mesothelioma
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
This phase I/II trial studies the side effects and how well pembrolizumab with or without anetumab ravtansine works in treating patients with mesothelin-positive pleural mesothelioma.
- Trial name
- NCT03126630
- Testing
- Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 33 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Mesothelioma, Solid Tumors
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
The phase I part of the study is a dose-finding study of escalating doses of CBP501 combined with full-dose cisplatin and pemetrexed in patients with histologically confirmed solid malignancy that is metastatic or unresectable…
- Trial name
- NCT00700336
- Testing
- pemetrexed, cisplatin and CBP501, pemetrexed and cisplatin, pemetrexed, cisplatin and CBP501, dose finding
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- CanBas Co. Ltd.
Malignant Mesothelioma, Metastatic Cancer
Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma
RATIONALE: Video-assisted surgery to remove part of the tissue layer covering the inside of the chest cavity may be effective in treating pleural effusion and cause less damage to normal tissue.
- Trial name
- MesoVATS (NCT00821860)
- Testing
- talc, therapeutic thoracoscopy, therapeutic videothoracoscopy
- Where
- 5 sites in United Kingdom
- Volunteers
- 196 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Mesothelioma
Serum Biomarkers in Diagnosis of Mesothelioma
In this study, the investigators analyzed the efficiencies of hyaluronan, osteopontin, C-ERC/mesothelin, N-ERC/mesothelin and syndecan-1 serum levels, both individually and in combination, in distinguishing malignant pleural…
- Trial name
- NCT02029105
- Testing
- Mesothelin, hyaluronan, osteopontin, syndecan-1
- Where
- Turkey (Türkiye)
- Volunteers
- 230 people
- Sponsor
- Eskisehir Osmangazi University
Pleural Mesothelioma, Metastatic Pleural Effusions
Gene Therapy for Pleural Malignancies
This Phase I study will evaluate the safety of two doses of BG00001 at different doses and intervals. Eligible subjects will have: malignant pleural mesothelioma, or pleural effusions who have progressed through at least one…
- Trial name
- NCT00299962
- Testing
- Adenoviral-mediated Interferon-beta, SCH 721015
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Pennsylvania
Mesothelioma, Malignant, Gene Abnormality
Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a rare pleural cancer, which could be primary or secondary to an asbestos exposure. To enhance our knowledge of this rare disease, an exploration of genetic and tumor mechanism is…
- Conditions
- Mesothelioma, Malignant, Gene Abnormality, Pleural Mesothelioma
- Trial name
- SCITH-MESO (NCT04823741)
- Testing
- PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.
- Conditions
- Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma, Urothelial Carcinoma
- Trial name
- NCT07532902
- Testing
- BMS-986504, Ipilimumab, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Pleural Mesothelioma
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM).
- Trial name
- NCT06037941
- Testing
- E-Nose testing, Research blood
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This phase II trial is studying how well erlotinib works in treating patients with malignant mesothelioma of the lung
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Trial name
- NCT00039182
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Mesothelioma
Four Versus Six Cycles of Pemetrexed/Platinum for MPM
The prognosis of mesothelioma is generally poor. The median survival of patients with unresectable malignant mesothelioma ranges approximately between 6-12 months. Survival is poor because there is no curative treatment.
- Trial name
- NCT02497053
- Testing
- pemetrexed/platinum chemotherapy
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Malignant Mesothelioma
Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients
This is an observational prospective analysis of biological characteristics of malignant mesothelioma (MM) patients. Frozen and paraffin-embedded tumor specimens and pleural effusion of patients will be collected and than will be…
- Trial name
- NCT02300883
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Armando Santoro, MD
Mesothelioma
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma
The aim of this study is to learn about how mesothelioma affects patients' emotional and physical well-being. Also, the investigators would like to learn more about what patients need and how they deal with this illness.
- Trial name
- NCT01356251
- Testing
- Questionnaires & online virtual support group
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pleural Neoplasms
Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
This study aims to determine how successful the chemotherapy regimen of Pemetrexed plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery.
- Trial name
- NCT00087698
- Testing
- pemetrexed, cisplatin
- Where
- 7 sites in United States
- Volunteers
- 77 people
- Sponsor
- Eli Lilly and Company
Malignant Pleural Mesothelioma
Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma
This is a prospective study evaluating the effect of expression of CD74 and VEGF on outcome of treatment in patients with malignant pleural mesothelioma receiving Pemetrexed/Platinum protocol.
- Trial name
- NCT02761863
- Testing
- CD 74, VEGF detection
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Malignant Mesothelioma, Pancreatic Cancer
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Malignant Mesothelioma, Pancreatic Cancer, Ovarian Tumor, Triple Negative Breast Cancer
- Trial name
- NCT02580747
- Testing
- anti-meso-CAR vector transduced T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Mesothelioma
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
Background: LMB-100 is a man-made protein. It is attracted to the mesothelin protein. This is found in many tumors, including mesothelioma. But it is found in only a very small number of normal tissues.
- Trial name
- NCT02798536
- Testing
- LMB-100, nab-paclitaxel
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Adult, Mesothelioma
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or…
- Conditions
- Solid Tumor, Adult, Mesothelioma, NSCLC
- Trial name
- NCT04665206
- Testing
- VT3989, Nivolumab & Ipilimumab, Osimertinib
- Where
- 12 sites in United States, Australia
- Volunteers
- 434 people
- Sponsor
- Vivace Therapeutics, Inc